Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ospemifene vs Conjugated Estrogens for Postmenopausal Sexual Dysfunction
NCT03018106Phase 4Terminated
- Sponsor
- Emory University
- Start
- Jun 2017
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ospemifene in Vulvovaginal atrophy (VVA) and dyspareunia (2 arms), sponsored by Emory University. Primary endpoints: Female Sexual Function Index at 12 weeks, Pain With Sex at 12 weeks and 3 more. Started Jun 2017; status: terminated.
02
Drugs
ospemifene
03
Conditions
Vulvovaginal atrophy (VVA)dyspareunia
Beyond the preview
Go deeper on NCT03018106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03018106.